TITLE

Metabolic syndrome is not associated with reduction in aortic distensibility in subjects with type 2 diabetes mellitus

AUTHOR(S)
Tentolouris, Nicholas; Papazafiropoulou, Athanasia; Moyssakis, Ioannis; Liatis, Stavros; Perrea, Despoina; Kostakis, Maria; Katsilambros, Nicholas
PUB. DATE
January 2008
SOURCE
Cardiovascular Diabetology;2008, Vol. 7, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Aortic distensibility (AD) is a marker of the elastic properties of the aorta. Reduction of AD occurs early in subjects with type 2 diabetes mellitus (T2DM) and it is associated with subclinical generalized atherosclerosis. Metabolic syndrome (MetS) is common in subjects with T2DM and predicts cardiovascular morbidity and mortality. This study examined the potential relationship between MetS and AD in a cohort of subjects with T2DM. Methods and results: A total of 210 subjects with T2DM were studied. MetS was diagnosed using the NCEP/ATP-III criteria. AD was assessed non-invasively by ultrasonography. The prevalence of MetS was 64.8%. AD was not significantly different between subjects with and without MetS (1.80 � 0.54 vs. 1.84 � 0.53 10-6 dyn-1 cm�, p = 0.55). Univariate linear regression analysis showed that AD was associated positively with male sex (p = 0.02) as well as glomerular filtration rate (p < 0.001), and negatively with age (p = 0.04), history of hypertension (p = 0.001), as well as duration of diabetes (p < 0.001). After multivariate adjustment, AD was associated independently and significantly only with age (p = 0.02), duration of diabetes p < 0.001), and history of hypertension (p = 0.004); no significant relationship was found with MetS status, the sum of the components of the MetS or the individual components-besides hypertension-of the MetS. Conclusion: In subjects with T2DM, MetS status per se is not associated with reduction of AD. In addition, it was shown that besides ageing, duration of glycemia was a strong predictor of AD. From the components of the MetS only hypertension was associated with reduction of the elastic properties of the aorta.
ACCESSION #
55716367

 

Related Articles

  • Association of HMGB1 and esRAGE levels with carotid atherosclerosis in type 2 diabetes mellitus. HU Xiao-jiao; JING Ai-yu; XIE Xuan; WU Juan-juan; ZHANG Jing; TENG Yun // Journal of Xi'an Jiaotong University (Medical Sciences);Sep2013, Vol. 34 Issue 5, preceding p638 

    Objective To explore the relationship of high mobility group box-1 protein (HMGB1) and endogenous secretory receptor for advanced glycation end products (esRAGE) with carotid atherosclerosis (AS) in type 2 diabetes mellitus (T2DM). Methods We recruited 198 hospitalized patients as the patient...

  • Fatty Liver Increases the Association of Metabolic Syndrome With Diabetes and Atherosclerosis. JUÁREZ-ROJAS, JUAN G.; MEDINA-URRUTIA, AIDA X.; JORGE-GALARZA, ESTEBAN; GONZÁLEZ-SALAZAR, CARMEN; KIMURA-HAYAMA, ERIC; CARDOSO-SALDAÑA, GUILLERMO; POSADAS-SÁNCHEZ, ROSALINDA; MARTÌNEZ-ALVARADO, ROCIO; POSADAS-ROMERO, CARLOS // Diabetes Care;Jun2013, Vol. 36 Issue 6, p1726 

    OBJECTIVE--To analyze the participation of fatty liver (FL) in the association of metabolic syndrome (MS) with type 2 diabetes and coronary artery calcification (CAC). RESEARCH DESIGN AND METHOD--A total of 765 subjects (52% women) aged 30 to 75 years without clinical atherosclerosis were...

  • Serum Levels of Adipocyte Fatty Acid-Binding Protein Are Associated with the Severity of Coronary Artery Disease in Chinese Women. Yuqian Bao; Zhigang Lu; Mi Zhou; Huating Li; Ye Wang; Meifang Gao; Meng Wei; Weiping Jia // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    Background: Adipocyte fatty acid-binding protein (A-FABP) has been described as a novel adipokine, playing an important role in the development of metabolic syndrome, type 2 diabetes and atherosclerosis. In this study, we investigated the relationship between serum levels of A-FABP and the...

  • Impact of a community-based lifestyle intervention program on health-related quality of life. Eaglehouse, Yvonne; Schafer, Gerald; Arena, Vincent; Kramer, M.; Miller, Rachel; Kriska, Andrea; Eaglehouse, Yvonne L; Schafer, Gerald L; Arena, Vincent C; Kramer, M Kaye; Miller, Rachel G; Kriska, Andrea M // Quality of Life Research;Aug2016, Vol. 25 Issue 8, p1903 

    Background: The presence of risk factors for type 2 diabetes and cardiovascular disease, or the conditions themselves, contributes to lower health-related quality of life (HRQoL) among adults. Although community-based lifestyle intervention programs have been shown to be effective...

  • The Utility of Carotid Ultrasonography in Identifying Severe Coronary Artery Disease in Asymptomatic Type 2 Diabetic Patients Without History of Coronary Artery Disease. IRIE, YOKO; KATAKAMI, NAOTO; KANETO, HIDEAKI; NISHIO, MAYU; KASAMI, RYUICHI; SAKAMOTO, KEN'YA; UMAYAHARA, YUTAKA; SUMITSUJI, SATORU; UEDA, YASUNORI; KOSUGI, KEISUKE; SHIMOMURA, IICHIRO // Diabetes Care;May2013, Vol. 36 Issue 5, p1327 

    OBJECTIVE--Although many studies have shown that carotid intima-media thickness (IMT) is associated with coronary artery disease (CAD), it remains inconclusive whether assessment of carotid IMT is useful as a screening test for asymptomatic but severe CAD in diabetic patients. RESEARCH DESIGN...

  • Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Hayden, Melvin R.; Tyagi, Suresh C. // Cardiovascular Diabetology;2002, Vol. 1, p3 

    Metabolic syndrome, insulin resistance, prediabetes, and overt type 2 diabetes mellitus are associated with an accelerated atherosclerosis (atheroscleropathy). This quartet is also associated with multiple metabolic toxicities resulting in the production of reactive oxygen species. The redox...

  • The Metabolic Syndrome.  // Current Medical Literature: Diabetes;2006, Vol. 23 Issue 1, p22 

    The article presents abstracts of research on metabolic syndrome. These include "Insulin Resistance, the Metabolic Syndrome, and Incident Cardiovascular Events in the Framingham Offspring Study," by M. K. Rutter, J. B. Meigs and L. M. Sullivan, "Liver Markers and Development of the Metabolic...

  • From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators. Dagdelen, Selcuk // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Jan2008, Vol. 2 Issue 1, p24 

    Worldwide epidemic of type 2 diabetes mellitus, obesity, dyslipidemia, hypertension and atherosclerosis (i.e. metabolic syndrome) still requires further treatment strategies. Life style change can be regarded as single evidenced option to manage these co-morbid conditions, at the same time....

  • Hepatic steatosis, carotid atherosclerosis and metab olic syndrome: the STEATO Study. Carallo, Claudio; Mancuso, Gerardo; Mauro, Gaetano; Laghi, Ferdinando; Madafferi, Bruno; Irace, Concetta; Gnasso, Agostino; Scavelli, Faustina; Dell’Aquila, Ferruccio; Bartone, Mosè; Gullo, Francesco; Ferraro, Maria; Spagnuolo, Vitaliano; Belmonte, Maria; Ferrara, Antonio; Rotondaro, Antonio; Brandolino, Nicola; Parasporo, Francesca; Scopelliti, Francesco // Journal of Gastroenterology;Nov2009, Vol. 44 Issue 11, p1156 

    Hepatic steatosis is frequently observed in subjects with metabolic syndrome (MS). In type 2 diabetics, it is independently associated with cardiovascular diseases. In order to confirm and extend this finding, a large group of patients with risk factors for atherosclerosis was studied. Carotid...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics